GLEAMER
Acquired by
RADNET
GLEAMER acquired by RADNET
Target
GLEAMER
Acquirer
RADNET
Context
RadNet acquired Gleamer in an all-cash transaction to integrate its automated diagnostic and reporting solutions into the DeepHealth platform. The acquisition aims to create the world's largest provider of clinical radiology AI solutions by combining RadNet's massive US imaging volume with Gleamer's advanced multi-modality software. Gleamer will now operate as RadNet’s French subsidiary, with founder Christian Allouche continuing to lead development from Paris. The strategic goal is to automate routine imaging workflows—specifically plain-film X-rays, which represent 25% of RadNet’s volume—to drive significant cost efficiencies and diagnostic accuracy.
GLEAMER, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (13.3x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Gleamer is a leading French MedTech company specializing in artificial intelligence for medical imaging. Its "Copilot" platform provides automated diagnostic assistance for radiologists across multiple modalities, including X-ray, Mammography, and MRI. Prior to this acquisition, Gleamer consolidated the market by acquiring Pixyl and Caerus Medical in 2025, expanding its expertise into neuro and lumbar MRI. The company serves over 700 clients in 44 countries, with its solutions supporting over 25 clinical indications.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with GLEAMER
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 06/2023 | SUPERNOVA INVEST / HEAL CAPITAL | GLEAMER | FRANCE | Healthcare Services | Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs. A significant portion of the capital is earmarked for strengthening commercial and technical teams in Europe and the United States, as well as deepening strategic partnerships with global medical imaging equipment manufacturers (OEMs). |
REFERENCES
Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Target: gleamer